Age-related Survival Declines in Turkish Patients with Cutaneous Melanoma: A Retrospective Analysis

Age-related Survival Declines in Turkish Patients with Cutaneous Melanoma: A Retrospective Analysis

Authors

  • Faruk Tas Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey
  • Kayhan Erturk Department of Medical Oncology, Prof. Dr. Cemil Tascioglu Teaching Hospital, University of Health Sciences, Istanbul, Turkey

Keywords:

Melanoma, Age-related survival, Older patients, Prognosis, Turkey

Abstract

Introduction: In cancer patients, the age of a patient at the time of diagnosis is considered among the important clinical indicators.

Objectives: We aimed to investigate this significance in melanoma patients by creating patient age groups.

Methods: A total of 1,496 adult skin melanoma patients were evaluated retrospectively. Patients were divided into 6 age groups: under 30 (<30), 31-39 (30s), 40-49 (40s), 50-59 (50s), 60-69 (60s) and 70 and older (70+).

Results: The median age was 52 years (range 16-104), and the most common age group was the 50s (n=340, 22.7%). As age increased, so did the Clark level (P=0.0001), the rate of ulceration (P=0.0001), and the rate of BRAF wild-type (P=0.002). The recurrence rates of early-stage patients were similar for all age groups. A significant overall survival (OS) advantage was found only between the following age groups: <30 and 60s (P=0.04) and <30 and 70+ (P=0.01). Five-year OS were, from young to old: 70.5%, 66%, 63.1%, 66.3%, 57.2%, and 46.8%. A significant OS advantage was found only between the following age groups: <30 and 60s (P=0.04) and <30 and 70+ (P=0.01). The 70+ group had significantly worse OS rates in all age groups (<30: P=0.0001; 30s P=0.0001; 40s: P= 0.001; 50s: P=0.0001; and 60s: P=0.04).

Conclusions: While some unfavorable histopathological prognostic factors are associated more frequently with increasing age, clinical stage and recurrence do not differ significantly between age groups. A possible explanation for this might be that the elderly have more comorbidities and die of different causes.

References

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. DOI: 10.3322/caac.21763. PMID: 36633525.

Gershenwald JE, Scolyer RA, Hess KR, , et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67(6):472–492. DOI: 10.3322/caac.21409. PMID: 29028110.

Tas F, Erturk K. Median age of cutaneous melanoma presentation in Turkey from a single tertiary center is younger than Western countries. Indian J Surg. 2023;85(4):1010–1011. DOI: 10.1007/s12262-022-03566-2

Balch CM, Soong SJ, Gershenwald JE, , et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–3634. DOI: 10.1200/JCO.2001.19.16.3622. PMID: 11504744.

Balch CM, Soong SJ, Gershenwald JE, , et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20(12):3961–3968. DOI: 10.1245/s10434-013-3100-9. PMID: 23838920.

Rutkowski P, Nowecki ZI, Zdzienicki M, , et al. Cutaneous melanoma with nodal metastases in elderly people. Int J Dermatol. 2010;49(8):907–913. DOI: 10.1111/j.1365-4632.2009.04386.x. PMID: 21174374.

Tas F, Erturk K. Patient age and cutaneous malignant melanoma: elderly patients are likely to have more aggressive histological features and poorer survival. Mol Clin Oncol. 2017;7(6):1083–1088. DOI: 10.3892/mco.2017.1439. PMID: 29285379.

Tas F, Erturk K. Cutaneous melanoma in vicenarians: patients in their twenties and older patients show similar clinical behaviors and survival rates. J Cosmet Dermatol. 2020;19(10):2692–2696. DOI: 10.1111/jocd.13314. PMID: 32003530.

Van der Kooij MK, Wetzels MIAL, Aarts MJB, , et al. Age does matter in adolescents and young adults versus older adults with advanced melanoma; A national cohort study comparing tumor characteristics, treatment pattern, toxicity and response. . Cancers 2020;12(8), 2072 DOI: 10.3390/cancers12082072. PMID: 32726988.

Downloads

Published

2025-04-30

How to Cite

1.
Tas F, Erturk K. Age-related Survival Declines in Turkish Patients with Cutaneous Melanoma: A Retrospective Analysis. Dermatol Pract Concept. 2025;15(2):4936 . doi:10.5826/dpc.1502a4936

Share